

David Kenneth WHYNES

19 April 2017

Date of birth: 9 June 1949
Address: School of Economics, University of Nottingham, University Park, Nottingham
NG7 2RD, United Kingdom
Telephone: 0115 951 5463
FAX: 0115 951 4159
E-mail: david.whynes@nottingham.ac.uk
Web: <http://www.nottingham.ac.uk/economics/staff/details/Dkw.htm>

Pre-university education

- The Ecclesbourne School, Duffield, Derby.
- The Perse School, Cambridge.
- Cambridgeshire College of Arts and Technology, Cambridge.
- 12 O-levels, 5 A-levels (Chemistry, Economic History, Economics, Mathematics, Physics).

University education

1968-71 Bachelor of Arts (Upper Second, Joint Honours in Politics and Economics), University of York.
1971-72 Master of Letters (Economic Development), University of St.Andrews. Degree awarded 1974.
1974-76 Bachelor of Philosophy (Southern African Studies), University of York (part time).

Appointments

1973-75 Research Fellow, Institute for Social and Economic Research, University of York.
1976-88 Lecturer in Economics, University of Nottingham.
1988-93 Senior Lecturer in Economics, University of Nottingham.
1993-98 Reader in Health Economics, University of Nottingham.
1998-2015 Professor of Health Economics, University of Nottingham.
2016- Professor Emeritus, University of Nottingham.

Teaching record

Year 1: Economic Perspectives, Social Economics, Macroeconomics, Quantitative Methods.
Year 2: Social Economics, Quantitative Methods, Public Sector Economics.
Year 3: Health Economics, Provision of Public Goods, Economic Planning, Natural Resources, Econometrics.
Year 4: Pharmaco-economics (Pharmacy).
Masters: Research Methodology; Political Economy & Political Culture (with Politics); Evaluation Techniques, Health Economics (Community Health Sciences).

PUBLICATIONS

BOOKS (as author)

1979

The Economics of Third World Military Expenditure {pp.170}. London: Macmillan (UK); Austin: University of Texas Press (USA).

Macroeconomic Planning (with Bowles) {pp.202}. London: Allen and Unwin (Routledge, 2015).

1981

The Economic Theory of the State (with Bowles) {pp.236}. Oxford: Martin Robertson (UK); New York: St. Martin's Press (USA). Translated into Portuguese (Zahar Editores, 1982) and French (Editions Labor, 1986).

1983

Invitation to Economics {pp.230}, Oxford: Martin Robertson/Basil Blackwell. Translated into Italian (Editori Riuniti, 1985).

Comparative Economic Development {pp.340}, London: Butterworths.

1992

Welfare State Economics {pp.92}, Oxford: Heinemann Educational.

1997

Prescribing, budgets and fundholding in general practice (with Baines and Tolley) {pp.26}. London: Office of Health Economics (OHE peer-reviewed monograph No.125).

BOOKS (as editor)

1984

What is Political Economy ? {pp.243}. Oxford: Basil Blackwell.

1985

In Defence of Welfare (with Ferris and Bean) {pp.282}. London: Tavistock Publications.

1986

Barbara Wootton: Social Science and Public Policy - Essays in her Honour (with Bean) {pp.291}. London: Tavistock Publications.

1991

Policing and Prescribing: the British System of Drug Control (with Bean) {pp.282}, London: Macmillan.

1993

Current Issues in the Economics of Welfare (with Barr) {pp.247}, London: Macmillan (UK); New York: St.Martin's Press (USA). Translated into Mandarin (1999).

JOURNAL ARTICLES (peer-reviewed)

1974

The measurement of comparative development: a survey and critique. *Journal of Modern African Studies*, 12: 89-107.

1978

A production function analysis of English maternity hospitals (with Lavers). *Socio-Economic Planning Sciences*, 12: 85-93.

1987

On assessing efficiency in the provision of local government services. *Local Government Studies*, 13: 53-68.

1988

Knowledge of drugs and alcohol consumption among Nottingham 15-year olds (with Bean, Giggs and Wilkinson). *Health Education Journal*, 47: 79-81.

Homeless people in Nottingham (with Giggs). *East Midlands Geographer*, 11: 57-67.

1989

Managing drug use (with Bean, Giggs and Wilkinson). *British Journal of Addiction*, 84: 533-540.

Screening and the costs of treating colorectal cancer: some preliminary results (with Tuck, Walker, Pye, Hardcastle and Chamberlain). *Public Health*, 103: 413-419.

Class A drug users: prevalence and characteristics in Greater Nottingham (with Bean, Giggs and Wilkinson). *British Journal of Addiction*, 84: 1473-1480.

1990

Reported health problems and the socio-economic characteristics of the single homeless. *British Journal of Social Work*, 20: 355-364.

Why do the young homeless leave home ? (with Ferris). *Youth and Policy*, 31: 36-39.

Haemocult test and colorectal cancer (with Walker and Hardcastle). *Gastroenterology*, 99: 608 {Letter}.

The costing of nursing care: a study of 65 colorectal cancer patients (with Walker). *Journal of Advanced Nursing*, 15: 1305-1309.

1991

Retesting positive results in screening for colorectal cancer: a marginal analysis (with Walker, Thomas, Chamberlain and Hardcastle). *Applied Economics*, 23: 1015-1017.

The costs of screening for colorectal cancer (with Walker, Hardcastle and Chamberlain). *Journal of Epidemiology and Community Health*, 45: 220-224.

Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer: an economic perspective (with Walker and Hardcastle). *Scandinavian Journal of Gastroenterology*, 26: 215-218.

Participation and screening programmes for colorectal cancer: more would be better? (with Walker). *Journal of Health Economics*, 10: 207-225.

Homelessness and the intermediate accommodation sector: a demand and supply analysis. *Housing Studies*, 6: 96-111.

The hospital costs of diagnostic procedures for colorectal cancer (with Walker, Chamberlain and Hardcastle). *Journal of Clinical Epidemiology*, 44: 907-914.

Mobility and the single homeless. *Area*, 23: 111-118. {Reported as an editorial article in *Geographical*, December: 4-5}.

Illicit drugs production and supply-side drugs policy in Asia and South America. *Development and Change*, 22: 475-496.

1992

What does a university add to its local economy ? (with Bleaney, Binks, Greenaway and Reed). *Applied Economics*, 24: 305-311.

Filtering strategies in mass population screening for colorectal cancer: an economic evaluation (with Walker). *Medical Decision Making*, 12: 2-7.

Cost-effective screening strategies for colorectal cancer (with Walker and Hardcastle). *Journal of Public Health Medicine*, 14: 43-49.

Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas (with Walker and Hardcastle). *Health Economics*, 1: 53-60.

What type of postgraduate education do general practitioners want ? (with Falk-Whynes). *Postgraduate Education for General Practice*, 3: 147-151.

The health of the Nottingham homeless (with Giggs). *Public Health*, 106: 307-314.

The growth of UK health expenditure. *Social Policy and Administration*, 26(4): 285-295.

The effect of subject age on the costs of screening for colorectal cancer (with Walker and Hardcastle). *Journal of Epidemiology and Community Health*, 46: 577-581.

Health economics and cancer care. *Journal of Cancer Care*, 1: 131-137.

1993

Prevention of colorectal cancer by once-only sigmoidoscopy (with Atkin, Cuzick and Northover). *The Lancet*, 341: 736-740.

Economic recession and the welfare state. *Economics and Business Education*, 1(4): 172-177.

Convergent validity of two measures of quality of life (with Neilson). *Health Economics*, 2 (3): 229-235.

Screening and the costs of treating colorectal cancer (with Walker, Chamberlain and Hardcastle). *British Journal of Cancer*, 68: 965-968.

Can performance monitoring solve the public services' principal-agent problem ? *Scottish Journal of Political Economy*, 40(4): 434-446.

Counting the true costs of palliative care. *Progress in Palliative Care*, 1(2): 47-50.

The NHS internal market: economic aspects of its medium-term development. *International Journal of Health Planning and Management*, 8(2), 107-122.

1994

Cost comparison of domiciliary and hospital-based stroke rehabilitation (with Gladman and Lincoln). *Age and Ageing*, 23: 241-245.

Colorectal cancer screening and quality of life (with Neilson, Robinson and Hardcastle). *Quality of Life Research*, 3 (3): 191-198.

Fundholders' referral patterns and perceptions of service quality in hospital provision of elective general surgery (with Reed). *British Journal of General Practice*, 44: 557-560.

1995

The cost-effectiveness of cancer therapy: the health economist's view. *Proceedings of the Royal College of Physicians of Edinburgh*, 8(1): 67-75.

On approximations in treatment costing (with Walker). *Health Economics*, 4(1): 31-39.

Potential for cost economies in guiding therapy in patients with metastatic breast cancer (with Robertson, Dixon and Blamey). *British Journal of Cancer*, 72: 174-177.

Determinants of persistent compliance with screening for colorectal cancer (with Neilson). *Social Science and Medicine*, 41: 365-374.

GP fundholding and the costs of prescribing (with Baines and Tolley). *Journal of Public Health Medicine*, 17: 323-329.

Importance-performance analysis as a guide for hospitals in improving their provision of services (with Reed). *Health Services Management Research*, 8: 268-277.

The priority-setting exercise: an instrument for training in health care resource allocation (with Tolley). *Medical Teacher*, 17(4): 391-398.

Effect of retesting with dietary restriction in Haemoccult screening for colorectal cancer (with Robinson, Moss, Chamberlain, Mangham and Hardcastle). *Journal of Medical Screening*, 2: 41-44.

Is an immunological faecal occult blood test better than Haemoccult?: a cost-benefit study (with Robinson, Marks, Farrands, Bostock and Hardcastle). *European Journal of Surgical Oncology*, 21: 261-264.

Cost-effectiveness of screening for colorectal cancer: a simulation model (with Neilson). *IMA Journal of Mathematics Applied in Medicine and Biology*, 12: 355-367.

Optimal times of transfer between therapies: a mathematical framework. *Journal of Health Economics*, 14(4): 477-490.

1996

Explaining variations in general practice prescribing cost per ASTRO-PU (age, sex and temporary resident originated prescribing unit) (with Baines and Tolley). *British Medical Journal*, 312: 488-489.

Selection bias in GP fundholding (with Baines). *Health Economics*, 5 (2): 129-140.

Towards an evidence-based national health service? *The Economic Journal*, 106: 1702-1712.

The provision and finance of long-term care in the United Kingdom. *Geneva Papers on Risk and Insurance*, 21: 271-283.

Explaining variations in the frequency of night visits in general practice (with Baines). *Family Practice*, 13: 174-178.

Predicting activity and workload in general practice from the demographic structure of the practice population (with Baines). *Journal of Health Services Research and Policy*, 1(3): 128-134.

Measuring the efficiency of prescribing by general practitioners (with Bates and Baines). *Journal of the Operational Research Society*, 47: 1443-1451.

General practitioners' choice of referral destination: a probit analysis (with Reed and Newbold). *Managerial and Decision Economics*, 17: 587-594.

The costs of prescribing in dispensing practices (with Baines and Tolley). *Journal of Clinical Pharmacy and Therapeutics*, 21: 343-348.

1997

General practitioner fundholding and prescribing expenditure control: evidence from a rural English health authority (with Baines and Tolley). *PharmacoEconomics*, 11(4): 350-358.

Prescribing costs in UK general practice: the impact of hard budget constraints (with Baines and Tolley). *Applied Economics*, 29: 393-399.

Over-the-counter drugs and prescribing in general practice (with Baines). *British Journal of General Practice*, 47: 221-224.

GP fundholding and the costs of prescribing - further results (with Baines and Tolley). *Journal of Public Health Medicine*, 19: 18-22.

Prescribing cost savings by GP fundholders: long-term or short-term ? (with Avery and Heron). *Health Economics*, 6: 209-211.

Symptoms before and after surgery for colorectal cancer (with Neilson). *Quality of Life Research*, 6(1): 61-66.

Interferon- β in multiple sclerosis: can we control its costs ? (with Tolley). *PharmacoEconomics*, 11(3): 210-215.

Nottingham's pregnancy diary: a method of evaluating maternity care (with Pitman, Bailey and James). *British Journal of Midwifery*, 5 (10): 630-637.

GP fundholding and prescribing in UK general practice: evidence from two rural English Family Health Services Authorities (with Baines, Tolley, Phillips and Brigham). *Public Health*, 111: 321-325.

1998

Faecal occult blood screening for colorectal cancer: is it cost-effective ? (with Walker, Neilson and Hardcastle). *Health Economics*, 7: 21-29.

Entrepreneurship and innovation amongst GP fundholders (with Ennew, Jolleys and Robinson). *Public Money and Management*, 18(1): 59-64.

Income-based incentives in UK general practice (with Baines). *Health Policy*, 43: 15-31.

Analysing efficiency in general practice: an application of data envelopment analysis (with Baines and Bates). *Health Services Management Research*, 11: 1-6.

The costs of treating breast cancer in the United Kingdom: implications for screening (with Smith and Wolstenholme). *International Journal of Technology Assessment in Health Care*, 14(2): 277-289.

The use of the ASTRO-PU and the ASTRO(97)-PU in the setting of prescribing budgets in English general practice (with Baines). *Journal of Clinical Pharmacy and Therapeutics*, 23: 229-234.

Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries (with Newell, Dabis and Tolley). *AIDS*, 12: 1571-1580.

The ethics of resource allocation: the views of general practitioners in Lincolnshire, UK (with Baines and Tolley). *Social Science and Medicine*, 47: 1555-1564.

Stage-specific treatment costs for cervical cancer in the United Kingdom (with Wolstenholme). *European Journal of Cancer*, 34(12): 1889-1893.

General practitioners' referral thresholds and choices of referral destination: an experimental study (with Earwicker). *Health Economics*, 7: 711-722.

1999

The costs of treating lung cancer in the United Kingdom (with Wolstenholme). *British Journal of Cancer*, 80 (1/2): 215-218.

Entrepreneurial attitudes of primary health care physicians in the United Kingdom (with Feighan and Ennew). *Journal of Economic Behavior and Organisation*, 38: 331-347.

Controlled trial of pharmacist intervention in general practice: the effect on prescribing costs (with Rodgers, Avery and others). *British Journal of General Practice*, 49: 717-720.

Estimating time and travel costs incurred in clinic-based screening: flexible sigmoidoscopy screening for colorectal cancer (with Atkin, Wolstenholme and Frew). *Journal of Medical Screening*, 6(3): 119-123.

Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial. *Critical Reviews in Oncology/Hematology*, 32(2): 155-165.

Trends in acute admissions: a study of one English District General Hospital (with Falk-Whynes and Pringle). *Journal of Public Health Medicine*, 21(4): 459-463.

2000

Measuring concentration in primary care (with Thornton). *Health Care Management Science*, 3(1): 43-49.

Improving the cost-effectiveness of colorectal cancer screening (with Atkin). *Journal of the National Cancer Institute*, 92: 513-514 {Editorial}.

A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs (with Avery and others). *British Medical Journal*, 321: 276-281.

An economic evaluation of occupational health (with Miller and Reid). *Occupational Medicine*, 50(3): 159-163. {Winner of the Esso Prize for the Best Paper of 2000}.

Cigarette consumption in the Netherlands 1970 – 1995: does tax policy encourage the use of hand-rolling tobacco ? (with Mindell). *European Journal of Public Health*, 10: 214-219.

Prevention of mother-to-child transmission of HIV in developing countries: recommendations for practice. The Ghent International Working Group on Mother-To-Child Transmission of HIV (with Dabis and others). *Health Policy and Planning*, 15(1): 34-42.

2001

Evaluating maternity services: how representative are data collected using a pregnancy diary ? (as the "Nottingham Pregnancy Diary Research Group"). *Public Health*, 115: 108-113.

Mass population screening for colorectal cancer: factors influencing subjects' choice of screening test (with Frew and Wolstenholme). *Journal of Health Services Research and Policy*, 6(2): 85-91.

- The role of community pharmacists in prescribing medication for the treatment of head lice (with Philips, Parnham, Slack and Earwicker). *Journal of Public Health Medicine*, 23(2): 114-120.
- Collaborating with a primary care-based research network (with Frew, Hammersley and Wolstenholme). *Journal of Evaluation in Clinical Practice*, 7(3): 339-342.
- Willingness-to-pay for colorectal cancer screening (with Frew and Wolstenholme). *European Journal of Cancer*, 37(14): 1746-1751.
- Early withdrawal from cervical cancer screening: the question of cost-effectiveness (with Philips). *European Journal of Cancer*, 37(14): 1775-1780.

2002

- Professional attitudes to *Changing Childbirth* in Nottingham, UK (with Holroyd, Bailey, James and Pitman). *International Journal of Nursing Studies*, 39: 177-186.
- Receipt of information and women's attitudes towards ultrasound scanning during pregnancy (for the "Nottingham Pregnancy Diary Research Group"). *Ultrasound in Obstetrics and Gynecology*, 19: 7-12.
- Primary care physicians' attitudes to health care reform in England (with Baines). *Health Policy*, 60(2): 111-132.
- The boundaries of cellular pathology: how pathologists see their clinical role (with Jenkins, Philips and Grisaffi). *Journal of Pathology*, 196(3): 356-363.
- Psychosocial and economic aspects of a trial of management of mild and borderline cervical abnormalities (TOMBOLA) (with Philips, Gray and Avis). *European Journal of Oncology Nursing*, 6(1): 23-29.
- Health care costs... *European Heart Journal*, 23(16): 1237-1239 {Editorial}.
- The economic case for faecal occult blood screening. *Annals of Oncology*, 13(12): 1953-1954 {Letter}.
- Communicating mild and borderline abnormal cervical smear results: how and what are women told ? (with Philips, Johnson and Avis). *Cytopathology*, 13(6): 355-363.

2003

- Eliciting willingness-to-pay: comparing closed-ended with open-ended and payment scale formats (with Frew and Wolstenholme). *Medical Decision Making*, 23(2): 150-159.
- Human papillomavirus and the value of screening: young women's knowledge of cervical cancer (with Philips, Johnson and Avis). *Health Education Research*, 18(3): 318-328.
- A comparison of two methods for eliciting contingent valuations of colorectal cancer screening (with Frew and Wolstenholme). *Journal of Health Economics*, 22(4): 555-574.
- The costs of flexible sigmoidoscopy screening for colorectal cancer in the United Kingdom (with Frew, Edwards and Atkin). *International Journal of Technology Assessment in Health Care*, 19(2): 384-395.
- Evidence of improving cost-effectiveness of pediatric cochlear implantation (with Sach, O'Neill, Archbold and Donoghue). *International Journal of Technology Assessment in Health Care*, 19(2): 421-431.
- Colorectal cancer, screening and survival: the influence of socio-economic deprivation (with Frew, Manghan, Scholefield and Hardcastle). *Public Health*, 117(6): 389-395.

Measuring indirect costs: is there a problem ? (with Sach). *Applied Health Economics and Health Policy*, 2(3): 135-139.

2004

Willingness-to-pay for pediatric cochlear implantation (with Sach, O'Neill, O'Donoghue and Archbold). *International Journal of Pediatric Otorhinolaryngology*, 68(1): 91-99.

Economics of cancer screening programs. *Expert Review of Pharmacoeconomics and Outcomes Research*, 4(1): 61-69.

Innovation and funding specialist services: cochlear implantation (with Sach, Parker and Archbold). *Journal of Health, Organization and Management*, 18(1): 53-63.

Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer (with Renehan and O'Dwyer). *British Medical Journal*, 328: 81-84.

Evidence of range bias in contingent valuation payment scales (with Frew and Wolstenholme). *Health Economics*, 13(2): 183-190.

Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial. *Journal of Medical Screening*, 11(1):11-15.

Comparing willingness-to-pay: bidding game format vs. open-ended and payment scale formats (with Frew and Wolstenholme). *Health Policy*, 68(3): 289-298.

Women's interpretation of cervical smear test results (with Philips and Avis). *Cytopathology*, 15(3): 142-147.

2005

Eliciting relative preferences for two methods of colorectal cancer screening (with Frew and Wolstenholme). *European Journal of Cancer Care*, 14(2): 124-131.

Estimating time and out-of-pocket costs incurred by families attending a paediatric cochlear implant programme (with Sach, O'Donoghue and Archbold). *International Journal of Pediatric Otorhinolaryngology*, 69(7): 929-936.

Developing a questionnaire to measure the psychosocial impact of an abnormal cervical smear result and its subsequent management: the TOMBOLA (Trial Of Management of Borderline and Other Low-Grade Abnormal smears) trial (with Gray, Sharp and others). *Quality of Life Research*, 14: 1553-1562.

Knowledge of cervical screening and screening amongst women in east-central England (with Philips and Avis). *International Journal of Gynecological Cancer*, 15(4): 639-645.

Paediatric cochlear implantation: the views of parents (with Sach). *International Journal of Audiology*, 44(7): 400-407.

Cervical cancer screening and perceived information needs (with Clarke, Philips and Avis). *Health Education*, 105(4): 289-303.

Think of a number...any number ? (with Frew and Philips). *Health Economics*, 14(11): 1191-1195.

Willingness-to-pay and demand curves: a comparison of results obtained using different elicitation formats (with Frew and Wolstenholme). *International Journal of Health Care Finance and Economics*, 5(4): 369-386.

2006

- Testing the construct validity of willingness to pay valuations using objective information about risk and health benefit (with Philips and Avis). *Health Economics*, 15(2): 195-204.
- Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors (with Gray, Sharp, Cotton and others). *British Journal of Cancer*, 94(9): 1253-1262.
- Accounting for the increase in NSAID expenditure: substitution or leakage ? (with Barton and Avery). *Cost Effectiveness and Resource Allocation*, 4: 9.
- Assessing progressivity of out-of-pocket payment: with illustration to Malaysia (with Yu and Sach). *International Journal of Health Planning and Management*, 21(3): 193-210.
- Introducing HPV triage into the English cervical cancer screening programme: consequences for participation (with Philips and Avis). *Women and Health*, 43(2): 17-34.
- Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122) (as “The ENOS Trial Investigators”). *International Journal of Stroke*, 1: 245–249.

2007

- A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow ? (with Sach and Smith). *Pharmacoeconomics*, 25(2): 107-127.
- Why do women participate in the English cervical cancer screening programme ? (with Philips and Avis). *Journal of Health Economics*, 26(2): 306–325.
- United Kingdom cervical cancer screening and the costs of time and travel (with Woolley, Philips, Cotton, Gray and others). *International Journal of Technology Assessment in Health Care*, 23(2): 232–239.
- WTP and WTA: do people think differently ? (with Sach). *Social Science & Medicine*, 65(5): 946–957.
- On the numerical forms of contingent valuation responses (with Frew, Philips, Covey and Smith). *Journal of Economic Psychology*, 28(4): 462-476.

2008

- Risk-stratified intensive follow up for treated colorectal cancer – realistic and cost saving ? (with Macafee and Scholefield). *Colorectal Disease*, 10(3): 222-230.
- Could CT screening for lung cancer ever be cost effective in the United Kingdom ? *Cost Effectiveness and Resource Allocation*, 6: 5.
- Equity in health care financing: the case of Malaysia (with Yu and Sach). *International Journal for Equity in Health*, 7: 15.
- A comparison of the performance of the EQ-5D and SF-6D for individuals aged >45 years (with Barton, Sach and others). *Health Economics*, 17(7): 815-832.
- Correspondence between EQ-5D health state classifications and EQ VAS scores (for the TOMBOLA Group). *Health and Quality of Life Outcomes*, 6: 94.
- Management of low-grade cervical abnormalities detected at screening: which method do women prefer ? (with Woolley and Philips, for the TOMBOLA Group). *Cytopathology*, 19(6), 355–362.

Population screening for colorectal cancer: the implications of an ageing population (with Macafee, Waller, Moss and Scholefield). *British Journal of Cancer*, 99(12): 1991–2000.

2009

Deprivation and self-reported health: are there “Scottish effects” in England and Wales ? *Journal of Public Health*, 31(1): 147-153.

Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study (as “TOMBOLA Group”). *British Medical Journal*, 339: b2549.

Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial (as “TOMBOLA Group”). *British Medical Journal*, 339: b2546.

Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial (as “TOMBOLA Group”). *British Medical Journal*, 339: b2548.

After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial (as “TOMBOLA Group”). *BJOG*, 116: 1506–1514.

Prospective randomized trial using cost–utility analysis of early versus delayed laparoscopic cholecystectomy for acute gallbladder disease (with Macafee, Humes and others). *British Journal of Surgery*, 96: 1031–1040.

Responsiveness of the EQ-5D to HADS-identified anxiety and depression (for the TOMBOLA Group). *Journal of Evaluation in Clinical Practice*, 15: 820-825.

Men and women: beliefs about cancer and about screening (with Sach). *BMC Public Health*, 9: 431.

Treated colorectal cancer: what is the cost to primary care ? (with Macafee, West and Scholefield). *Clinical Medicine: Oncology*, 3: 1-7.

Hospital costs of colorectal cancer care (with Macafee, West and Scholefield). *Clinical Medicine: Oncology*, 3: 27-37.

2010

Analysis of deaths occurring within the Nottingham trial of faecal occult blood screening for colorectal cancer (with Mangham, Balfour and Scholefield). *Gut*, 59(8): 1088-1093.

2011

Long-term psychosocial impact of alternative management policies in women with low-grade abnormal cervical cytology referred for colposcopy: a randomised controlled trial (with Sharp, Cotton and others). *British Journal of Cancer*, 104: 255-264.

Explaining variation in the uptake of HPV vaccination in England (with Kumar). *BMC Public Health*, 11: 172.

Reform towards national health insurance in Malaysia: the equity implications (with Yu and Sach). *Health Policy*, 100(2-3): 256-263.

CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report (with Field and others). *Thorax*, 66(8): 736-737 {Authors' response, 2013, 68(1):105}.

2012

- Sex, self-interest and health care priorities (with Sach). *Journal of Socio-Economics*, 41(1): 1-7.
- Which women default from follow-up cervical cytology tests? A cohort study within the TOMBOLA trial (with Sharp, Cotton and others). *Cytopathology*, 23(3): 150-160.
- Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up (with Scholefield, Moss, Mangham and Hardcastle). *Gut*, 61(7): 1036-1040.
- Cost effectiveness of epidural steroid injections to manage chronic lower back pain (with McCahon, Ravenscroft and Hardman) *BMC Anesthesiology* , 12: 26.
- Screening for colorectal cancer: how can we maximize uptake ? *Colorectal Cancer*, 1(6): 471-478.
- Who defaults from colposcopy ? A multi-centre, population-based, prospective cohort study of predictors of non-attendance for follow-up among women with low-grade abnormal cervical cytology (with Sharp, Cotton and others). *European Journal of Obstetrics & Gynaecology and Reproductive Biology*, 165(2): 318-325.

2013

- Responsiveness of the EQ-5D health-related quality-of-life instrument in assessing low back pain (with McCahon, Ravenscroft and others). *Value in Health*, 16(1): 124-132.
- Testing for differential item functioning within the EQ-5D (with Sprigg, Bath and others). *Medical Decision Making*, 33(2): 252-260.
- Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom (with Owens and Evangelou). *European Journal of Health Economics*, 14(2): 315-321.
- Evaluation of mammographic surveillance services in women aged 40–49 years with a moderate family history of breast cancer: a single-arm cohort study (with Duffy, Mackay and others). *Health Technology Assessment*, 17 (11): 1-95.
- Impact of alternative management policies on health-related quality of life in women with low-grade abnormal cervical cytology referred for colposcopy (with Cotton, Sharp and others). *European Journal of Obstetrics & Gynaecology and Reproductive Biology*, 169: 88-92.
- Does the correspondence between EQ-5D health state description and VAS score vary by medical condition ? *Health and Quality of Life Outcomes*, 11:155.
- Very low quality of life after acute stroke: data from the Efficacy of Nitric Oxide in Stroke trial (with Sprigg, Selby, Bath and others). *Stroke*, 44: 3458-3462.

2014

- The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening (with McRonald, Yadegarfar and others). *Cancer Prevention Research*, 7(3): 362-371.

2015

- Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation (with Lim, Brittain, Duley and others). *Health Technology Assessment*, 19(16): 1-78.

Cost comparison of re-usable and single-use fibrescopes in a large English teaching hospital (with McCahon). *Anaesthesia*, 70(6): 699-706.

A normal colposcopy examination fails to provide psychological reassurance for women who have had low-grade abnormal cervical cytology (with Cotton, Sharp and others). *Cytopathology*, 26(3): 178-187.

Cost-effectiveness of volar locking plate versus percutaneous fixation for distal radial fractures: economic evaluation alongside a randomised clinical trial (with Karantana, Davis and Scammell). *The Bone & Joint Journal*, 97-B: 1264-1270.

2016

Impact of post-colposcopy management on women's long-term worries: results from the UK population-based TOMBOLA trial (with Sharp, Cotton and others). *Journal of Family Planning and Reproductive Health Care*, 42(1): 43-51.

UK Lung Cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening (with Field, Duffy and others). *Thorax*, 71(2): 161-170.

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer (with Field, Duffy and others). *Health Technology Assessment*, 20(40): 1-146.

Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: protocol for a randomized, placebo-controlled trial (with Sprigg, Robson and others). *International Journal of Stroke*, 11(6): 683-694.

Sex, benevolence and willingness to pay for screening (with Sach). *International Journal of Social Economics*, 43(10): 982-997.

2017

Psychosocial morbidity in women with abnormal cervical cytology managed by cytological surveillance or initial colposcopy: longitudinal analysis from the TOMBOLA randomised trial (with Fielding, Rothnie and others). *Psycho-Oncology*, 26(4): 476-483.

CONTRIBUTIONS to research published in peer-reviewed journals

2002

Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a multicentre randomised trial (as "UK Flexible Sigmoidoscopy Screening Trial Investigators"). *Lancet*, 359: 1291-1300.

2004

Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial (Ozolins and others). *Lancet*, 364 (9452): 2188-2195.

2010

Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial (as “UK Flexible Sigmoidoscopy Screening Trial Investigators”). *Lancet*, 375(9726): 1624-33.

2013

Effect of the neutral CLOTS 1 trial on the use of graduated compression stockings in the Efficacy of Nitric Oxide Stroke (ENOS) trial (Ankolekar and others, for the ENOS Trial Investigators). *Journal of Neurology, Neurosurgery and Psychiatry*, 84: 342–347.

Factors associated with psychological distress following colposcopy among women with low-grade abnormal cervical cytology: a prospective study within the Trial Of Management of Borderline and Other Low-grade Abnormal smears (TOMBOLA) surveillance (Sharp and others, for the TOMBOLA Group). *Psychooncology*, 22(2): 368-380.

European randomized lung cancer screening trials: post NLST (Field and others, for the European Randomised Screening Trial Group). *Journal of Surgical Oncology*, 108: 280-286.

2014

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer (Primrose and others, for the FACS Trial Investigators). *Journal of the American Medical Association*, 311(3): 263-270.

The unintended consequences of cervical screening: distress in women undergoing cytologic surveillance (Sharp and others, for the TOMBOLA Group). *Journal of Lower Genital Tract Disease*, 18(2): 142-150.

Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial (as “ENOS Investigators”). *International Journal of Stroke*, 9(6): 711-720.

Measuring the psychosocial burden in women with low-grade abnormal cervical cytology in the TOMBOLA trial: psychometric properties of the Process and Outcome Specific Measure (POSM) (Rothnie and others, for the TOMBOLA Group). *Health and Quality of Life Outcomes*, 12: 154.

2015

Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial (as “The ENOS Trial Investigators”). *Lancet*, 385: 617-628.

Long-term worries after colposcopy: which women are at increased risk ? (Sharp and others, for the TOMBOLA Group). *Womens Health Issues*, 25(5): 517-527.

CONFERENCE ABSTRACTS (peer-reviewed)
1997

Cost-effectiveness of faecal occult blood screening for colorectal cancer: results from the Nottingham trial (with Walker and Neilson). *European Journal of Cancer*, 33 Supp 9: S12, OP30.

The cost of breast cancer: implications for screening (with Wolstenholme). *European Journal of Cancer*, 33 Supp 9: S12-13, OP31.

The cost of cervical cancer: implications for screening (with Wolstenholme). *European Journal of Cancer*, 33 Supp 9: S13, OP32.

1998

Avoidable acute admissions: change at the margins (with Falk-Whynes and others). *Association of University Departments of General Practice, Edinburgh*.

Avoidable acute admissions: margins for change (with Falk-Whynes and others). *Society for Social Medicine, Cardiff*.

1999

Private costs incurred in clinic-based screening: flexible sigmoidoscopy screening for colorectal cancer (with Frew and Wolstenholme), *International Society of Technology Assessment in Health Care, Edinburgh*: P246.

The cost-effectiveness of advances in technology in the treatment of acute myocardial infarction between 1982 and 1992 (with Johnson, Gray and Brown), *International Society of Technology Assessment in Health Care, Edinburgh*: P255.

2000

Young women's opinions on cervical screening: knowledge, valuation and perception of risk (with Johnson, Philips, Avis and Jenkins), *18th International Papillomavirus Conference, Barcelona*: P228.

The relationship between minor cervical abnormalities and HPV infection: what are women currently told and what do they understand ? (with Johnson, Philips, Avis and Jenkins), *18th International Papillomavirus Conference, Barcelona*: P229.

Early withdrawal from cervical cancer screening: would it be cost-effective ? (with Philips), *18th International Papillomavirus Conference, Barcelona*: P230.

Randomised controlled trial of four dyspepsia management strategies in primary care, with 12-month follow-up (with Duggan and others). *Gastroenterology*, 118(4) Supp. 2: A438.

Perceptions of pathology: how the profession sees itself (with Philips, Grisafi and Jenkins). *Royal Pathological Society of Great Britain and Ireland, Nottingham*: Abstract 110.

Cost-effective diagnosis and screening: just what the Health Service needs ? *Royal Pathological Society of Great Britain and Ireland, Nottingham*: Abstract 127.

Exclusion criteria in willingness-to-pay: do they make a difference ? (with Frew and Wolstenholme). *European Journal of Cancer*, 36 Supp 3: S2, OP8.

Health economics of TOMBOLA: trial of management of borderline and other low-grade abnormal smears (with Philips). *European Journal of Cancer*, 36 Supp 3: S5, OP17.

Early withdrawal from cervical cancer screening: would it be cost-effective ? (with Philips). *European Journal of Cancer*, 36 Supp 3: S8, OP31.

Willingness to pay for colorectal cancer screening: faecal occult blood testing vs. flexible sigmoidoscopy (with Frew and Wolstenholme). *European Journal of Cancer*, 36 Supp 3: S9, OP34.

2002

Knowledge of HPV and cervical screening (with Philips and Avis). *20th International Papillomavirus Conference, Paris*: O122.

Acceptability of HPV testing within the NHS cervical screening programme: some preliminary themes (with Philips and Avis). *20th International Papillomavirus Conference, Paris*: P397.

2003

Measuring costs. *5th International Multidisciplinary Congress, European Research Organisation on Genital Infection and Neoplasia, Paris*: SS18-02.

Willingness to pay and paediatric cochlear implantation (with Sach). *International Health Economics Association 4th. World Congress, San Francisco*.

A comparison of four methods of eliciting contingent valuations of colorectal cancer screening (with Frew and Wolstenholme). *International Health Economics Association 4th World Congress, San Francisco and European Journal of Cancer Supplement*. 1(3): PP6.

Acceptability of HPV testing as part of the UK cervical cancer screening programme (with Philips and Avis). *European Journal of Cancer Supplement*. 1(3): OP30.

Participation in cervical cancer screening: a decision-making framework (with Philips and Avis). *European Journal of Cancer Supplement*. 1(3): PP20.

Information and participation in cervical cancer screening: does it make a difference ? (with Philips and Avis). *European Journal of Cancer Supplement*. 1(3): PP21.

Assessing cost impact and economic benefits: the use of a decision model to select cancer patients with chemotherapy-related anemia for treatment with Epoetin Alfa (with Tolley, Zagari, Christopherson and Townsend). *European Journal of Cancer Supplement*. 1(3): PP31.

Distribution of colorectal cancers and adenomas in a screened population (with Macafee and Scholefield). *Gut*. 52 Supplement 1: 104.

2005

Would HPV testing be acceptable to UK women ? (with Philips and Avis). *International Health Economics Association 5th World Congress, Barcelona*.

Do respondents prefer willingness to pay to willingness to accept ? (with Sach). *International Health Economics Association 5th World Congress, Barcelona*.

Accounting for the increasing in NSAID prescribing: substitution or expansion ? (with Avery and Barton). *International Health Economics Association 5th World Congress, Barcelona*.

How do individuals select WTP values ? An explanation from prominence theory (with Frew, Philips, Smith and Covey). *International Health Economics Association 5th World Congress, Barcelona*.

A 'league table' of willingness-to-pay values across intervention, health problem, and country (with Smith and Sach). *International Health Economics Association 5th World Congress, Barcelona*.

The impact of private health payments in Malaysian households (with Yu and Sach). *International Health Economics Association 5th World Congress, Barcelona*.

2006

How equitable is the finance of health care ? The case of Malaysia (with Yu and Sach). *European Journal of Health Economics*. 7 Supp 1: 0518.

2007

Are people willing to pay for services from which they can't benefit directly ? (with Sach). *International Health Economics Association 6th World Congress, Copenhagen*.

Who pays more ? Household health expenditure in Malaysia (with Sach and Yu). *International Health Economics Association 6th World Congress, Copenhagen*.

2010

A cost-utility analysis of lumbar total disc replacement compared with circumferential spinal fusion (with Sundaram, Schrott and others). *Britspine Combined Meeting, Liverpool and 25th North American Spine Society meeting, Orlando, Florida – Spine Journal*, 10(9): S89-90.

2011

Evaluating the Edmonton frail scale as a screening tool for post-operative complications in older patients undergoing elective hip and knee surgery (with Gordon and others). *European Union Geriatric Medicine Society, Malaga, Spain*.

2012

Efficacy of Nitric Oxide in Stroke (ENOS) Trial: testing for differential functioning within the EQ-5D (with Bath and others). *21st European Stroke Conference, Lisbon, Portugal*.

Optimising cost-effectiveness in risk-based screening programmes: a modelling approach (with Sampson and James). *UK Health Economists Study Group & CES France, Marseilles, France*.

2013

United Kingdom Lung Cancer CT Screening Trial (UKLS) – awareness lessons learnt (UKLS investigators). *National Awareness and Early Diagnosis Research Conference, CRUK Institute, Cambridge*.

The uniqueness of the United Kingdom Lung Cancer Screening trial (UKLS) – a population screening study (UKLS investigators). *11th Annual British Thoracic Oncology Group Conference, Dublin*.

2015

Catastrophic health spending, non-communicable diseases and the role of children: a microeconomic analysis for China (with Liu and Bridges). *Royal Economic Society Conference, Manchester*.

Catastrophic health spending, non-communicable diseases and migration of children: a microeconomic analysis for China (with Liu and Bridges). *29th General Assembly of the European Society for Population Economics, Izmir, Turkey*.

2016

UK lung cancer screening trial (UKLS) cost effectiveness: similarities with the NLST high-risk quintiles (with Field and others). *Proceedings of the 107th annual meeting of the American Association for Cancer Research, New Orleans, USA - Cancer Research 76 (14 Suppl): Abstract 3458*.

JOURNAL ARTICLES (non-refereed)

1989

Young and homeless. *Benefits Research*, 4: 12-14.

1990

After 1992: the political economy of the Single European Act. *Economics*, 26: 19-23.

1991

Economic perspectives on the National Health reforms. *Economics*, 27: 108-112.

When the future is in futures. *Health Service Journal*, 101 (5246): 14-15.

1997

Saving graces (with Baines). *Health Service Journal*, 107 (5578): 24-25.

1998

The impact of fundholding on prescribing budgets (with Baines). *Prescriber*, 9 (5): 111-114.

Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial. *Deutsche Krebsgesellschaft Forum*, 13 (March/April): 109-111.

2000

HPV testing: how should decisions be made ? (with Philips and Jenkins). *Papillomavirus Report*, 11(5): 103-105.

2003

Screening for colorectal cancer in the UK: is it worthwhile ? (with Scholefield). *Surgery*, 21(7): iii-vi.

2004

Cancer: enough to make you screen ? *Hospital*, 6(1): R13-R14.

PAPERS in edited collections

1984

Introduction and Concluding Remarks. In: D.K.Whyne (ed.) *What is Political Economy ?*, Oxford: Basil Blackwell, 1-6 and 209-216.

International political economy. In: D.K.Whyne (ed.) *What is Political Economy ?*, Oxford: Basil Blackwell, 162-186.

1985

Markets and neo-liberal political economy. In: P.T.Bean, J.S.Ferris and D.K.Whyne (eds.) *In Defence of Welfare*, London: Tavistock Publications, 99-121.

1986

Is economics still lamentable ? In: P.T.Bean and D.K.Whyne (eds.) *Barbara Wootton: Social Science and Public Policy*, London: Tavistock Publications, 57-73.

1989

The political business cycle. In: D.Greenaway (ed.) *Current Issues in Macroeconomics*, London: Macmillan, 110-131.

The economic role of government as a constitutional problem. In: W.J.Samuels (ed.) *Fundamentals of the Economic Role of Government*, Westport: Greenwood Press, 205-211.

1990

Homelessness: facing the facts (with Ferris). In: S.Trench and T.Oc (eds.) *Current Issues in Planning*, Aldershot: Gower, 154-166.

1991

Drug problems, drug policies. In: D.K.Whynes and P.T.Bean (eds.) *Policing and Prescribing*, London: Macmillan, 1-14.

1992

The Colombian cocaine trade and the war on drugs. In: A.Cohen and F.R.Gunter (eds.) *The Colombian Economy: Issues of Trade and Development*, Boulder, Colorado: Westview Press, 329-352.

1993

Introductory issues (with Barr). In: N.Barr and D.K.Whynes (eds.) *Current Issues in the Economics of Welfare*, London: Macmillan, 1-19.

The poverty trap. In: N.Barr and D.K.Whynes (eds.) *Current Issues in the Economics of Welfare*, London: Macmillan, 63-86.

Health care expenditures. In: N.Gemmell (ed.) *The Growth of the Public Sector: Theory and International Evidence*, Oxford: Edward Elgar, 170-183.

Economic aspects of health care in the United Kingdom. In: G.B.H.Atkinson (ed.) *Developments in Economics: Volume 9*, Ormskirk: Causeway Press, 139-153.

1995

Long-term care for the elderly. In: Association of British Insurers (ed.) *Risk, Insurance and Welfare: the changing balance between public and private protection*, London: ABI, 26-36.

After 1992: the political economy of the Single European Act. In: N.M.Healey (ed.) *The Economics of the New Europe: from Community to Union*, 1995, London: Routledge, 157-169.

1996

Mass screening: European/UK perspective (with Bennett and Hardcastle). In: G.P.Young, B.Levin and P.Rozen (ed.) *Prevention and Early Detection of Colorectal Cancer*, London: W.B.Saunders Company, 275-288.

1997

The costs of palliative care. In: D.Clark, S.Ahmedzai and J.Hockley (ed.) *New Themes in Palliative Care*, Buckingham: Open University Press, 34-48.

1998

Entrepreneurial activity in the public sector: evidence from UK primary care (with Ennew and Feighan). In: P.Taylor-Gooby (ed.) *Choice and Public Policy: the Limits to Welfare Markets*, Basingstoke: Macmillan, 42-61.

2000

UK health care: re-organisation and rationing. In: G.B.H.Atkinson (ed.) *Developments in Economics: Volume 16*, Ormskirk: Causeway Press, 35-51.

2005

Intensive follow-up after colorectal cancer: recent successes and future challenges (with Renehan, Egger, Saunders and O'Dwyer). In: D.Cunningham, C.Topham, A.Miles (eds.) *The effective management of colorectal cancer*, London: Aesculapius Medical Press, 101-118.

RESEARCH REPORTS**1988**

A costing study of the diagnosis and treatment of colorectal cancer: implications for screening (with Hardcastle and others). Report to the Nuffield Provincial Hospitals Trust.

Drug taking in Nottingham and the links with crime (with Bean, Wilkinson and Giggs). Report to the UK Home Office Research and Planning Unit.

Nottingham Homelessness Study - research report (with Ferris and others). Community Policy Research Unit, University of Nottingham.

1989

Nottingham Homelessness Study - Homeless young people in Nottingham (with Ferris and Conway). Community Policy Research Unit, University of Nottingham.

An examination of the economic, legal, social, medical and ethical factors of drug policy in the UK and the Netherlands (15 authors). Report presented to the Commission of the European Communities by the Drug Policy Review Group, c/o Access Parliamentary Public Affairs, Stratford Place, London.

1991

Training needs for primary health care in Derbyshire (with Falk-Whynes and Adams). Report for Derbyshire Family Health Services Authority.

1993

Outcomes in oncology (with Hancock, Leonard and Aird). *Journal of Cancer Care*, 2: 137-142 {Conference proceedings}.

1994

Dementia: an economic assessment. Report for South Derbyshire Health Authority.

Evaluation of St. Barnabas hospice home support service (with Ahmedzai, Clark, Rayson and Brooks - Trent Palliative Care Centre). Report for Lincolnshire Health Authority.

A review of fundholding in Leicestershire with special emphasis on innovation in contracting (with Robinson, Jolleys and Ennew). Report for Leicestershire FHSA.

1996

Improving palliative care for Nottingham residents (with White, Ingleton, Daniel and Clark - Trent Palliative Care Centre). Report for Nottingham Health Authority.

1997

Cost-effectiveness and cost-benefit issues in the prevention of mother-to-child transmission of HIV. Report for the Ghent Working Group, UNAIDS and European Commission.

The economic impact of cancer in Trent (with Wolstenholme and Tolley). Report for Trent Health.

1998

Identifying how general practices make savings on their prescribing costs (with Avery and others). Report for the Department of Health.

1999

The evaluation of the LIZ GP incentives programme (with Bowler and others). Report for the Department of Health.

An investigation into recruitment and retention of GPs in North Thames region (with Bowler and others). Report for the Department of Health.

2000

An evaluation of the involvement of community pharmacists in counselling patients and prescribing medication for the treatment of head lice (with Philips and others). Report for Nottingham Health Authority and the Department of Health.

A scoping study concerning the evaluation of pricing information related to Immune Response Modifiers in relation to cervical screening programmes (with Gallivan and Jenkins). CORU Research Report 582, University College, London.

WORKING PAPERS**1976**

South African military expenditures - causes and consequences. Department of Economics Discussion Paper.

1977

The South African economy: a short-run macroeconomic model. Department of Economics Discussion Paper.

1978

Economics teaching in the universities: a survey of current practice. Department of Economics Discussion Paper. {Reported as an editorial article in *Times Higher Education Supplement*, 23 June: 8}.

1990

The changing characteristics of the single homeless. Department of Economics Discussion Paper.

1995

Entrepreneurship and innovation among GP fundholders: some preliminary evidence (with Ennew and Feighan). ESRC Economics Beliefs and Behaviour Programme Discussion Paper.

1998

General practitioners' views on current changes in the UK health service (with Baines and Cooper). Department of Economics Discussion Paper.

2003

Finance and performance of Portuguese hospitals (with Lima). Nucleo di Investigacao em Microeconomia Aplicada, Universidade do Minho, Working Paper 20.

2013

The relationship between individual risk and cost-effectiveness in screening interventions (with Sampson and James). Social Science Research Network, <http://ssrn.com/abstract=2362371> and University of Munich, <http://mpa.ub.uni-muenchen.de/51799/>